Lantern Pharma Newsletter December 2022

Lantern was ranked as the 16th (out of 380) most productive company for the use of AI in drug discovery by BioPharmaTrend, a top news provider of advanced technologies and AI for biopharma and biotech.

• Why it matters: The ranking further establishes RADR®, Lantern’s AI platform, as one of the top oncology focused AI platforms for drug discovery and development. Read how Lantern is using RADR® to advance its drug candidates from initial RADR® insight to late stage IND enabling studies in record times.
• Go deeper: Read the BiopharmaTrend article with the full rankings and their white paper on the 2022 key trends for AI in drug discovery and biotech.

1) Lantern has activated a third Harmonic™ clinical trial site, New York Cancer and Blood Specialists, which will host the trial at 8 different locations across New York.

• All three clinical trial sites, Gabrail Cancer Center, Northwest Oncology and New York Cancer and Blood Specialists, are in the process of screening patients and are targeting to enroll the first patients in Q1 2023.
• Multiple additional sites are expected to be activated in Q1 2023.

2) Harmonic™ in the news - The Harmonic™ trial was recently featured in a clinical trial spotlight article on OncLive, a high impact news site for oncologists about oncology news, clinical trials, and drug candidates. Read the full article here.

During Lung Cancer Awareness Month, Lantern partnered with the lung cancer advocacy group, Breath of Hope Kentucky (BOHKY), to raise awareness of issues facing never-smokers with lung cancer and to drive patient awareness for the Harmonic™ trial.

• As part of the campaign, Lantern and BOHKY featured the survivor stories of Dan and Brittany, who both received shocking diagnoses that they had lung cancer despite being never-smokers. Watch their inspirational survivor stories at the links below:
• Dan’s survivor story
• Brittany’s survivor story

What’s next: Next year, in collaboration with BOHKY, we will continue to share additional survivor stories of never-smokers with lung cancer, which will further drive awareness of the Harmonic™ trial in the never smoker-lung cancer community.

‍

Triple negative breast cancer (TNBC) is one of the most aggressive and malignant forms of breast cancer. Patients with TNBC have urgent needs for new therapies as they have no effective standard-of-care (SOC) therapy.

‍
New LP-184 results were presented at the San Antonio Breast Cancer Symposium (SABCS) that demonstrated its anti-tumor potency in preclinical TNBC models:

• LP-184 had low nano-molar potency (average IC50 of 297nM) when tested across a panel of 4 TNBC breast cancer cell lines.
• LP-184 was additionally tested in 10 patient derived xenograft (PDX) mouse models of TNBCs, 7 of which were resistant to Olaparib, a current SOC agent for TNBC. In all 10 TNBC PDX models, LP-184 treatment led to complete and durable tumor regression of 107-141%.

Go deeper: In addition to LP-184’s preclinical anti-tumor efficacy for primary TNBC tumors, LP-184 may also have added therapeutic potential to treat brain metastases (brain mets.) from TNBCs, which are found in ~14% of TNBC patients at their initial diagnosis.

‍
Each year in the US, there are approximately 8,000 newly diagnosed TNBC patients with an additional 21,000 relapsed TNBC patients, representing an annual market potential of up to $1.7 billion USD.

‍

New LP-284 preclinical data for mantle cell lymphoma (MCL), an aggressive subtype of B-cell non-Hodgkins lymphoma (NHL), were recently presented at the American Society of Hematology (ASH) annual meeting.

• LP-284 treatment was demonstrated to have between 91-105% greater tumor growth inhibition (TGI) in mice implanted with MCL cell derived xenograft (CDX) tumors, when compared to treatment with the standard-of-care (SOC) agents Ibrutinib or Bortezomib.
• In mouse MCL CDX tumors that had been treated and then grown resistant to either Ibrutinib or Bortezomib, subsequent LP-284 treatment of 4 mg/kg (i.v.) resulted in near complete tumor regression in the SOC resistant MCL CDX tumors (see figure above).
• In the large animal non-GLP toxicology portion of the IND enabling studies, the No Observed Adverse Effect Level (NOAEL) of LP-284 was found to be 0.3 mg/kg/dose.
• Taken together these results support the development of LP-284 as a novel agent for MCL and will help advance LP-
  284 towards a first in human Phase 1 clinical trial in mid 2023.
• The full results can be found on Lantern’s website.

Why it matters: Therapies for aggressive NHL’s, including MCL and double hit lymphoma’s (DHL), rarely achieve cures and have a high percentage of relapse and resistance. There are significant needs for additional late stage options for these patients.

‍
In the US and Europe, MCL and DHL are diagnosed in approximately 9,000 patients each year and have an estimated annual market potential of $1.2 billion USD.

‍